en.Wedoany.com Reported, March 28, 2026 – China's nuclear medicine field has reached a significant milestone: Atom High-Tech Co., Ltd. and the Spallation Neutron Source Science Center of the Chinese Academy of Sciences have officially signed a cooperation agreement to jointly advance the research, development, and industrialization of medical alpha isotopes. This collaboration focuses on key nuclides such as Actinium-225, Radium-223, and Lead-212, aiming to break through the bottlenecks in large-scale supply and promote the development of innovative targeted alpha therapy drugs.
The cooperation integrates the advantageous resources of both parties, forming a collaborative innovation model of "industry, academia, research, and application." The Spallation Neutron Source Science Center, relying on national major scientific facilities, has made breakthroughs in alpha isotope preparation and purification technology, mastering the core processes of key technologies. Atom High-Tech, leveraging its expertise in radiopharmaceutical R&D, production, and nationwide sales network, will drive the translation of these achievements from the laboratory to clinical practice. Both sides have identified three major tasks: first, to optimize processes to enhance production capacity and purity, laying a solid foundation for stable supply; second, to accelerate the transformation of nuclides into innovative drugs, shortening the time for patients to benefit; and third, to jointly cultivate interdisciplinary talent, building a core talent pool for the industry. The goal is to establish a national-level innovation and industrialization base for medical isotopes.
This collaboration holds profound significance for the upgrade of China's nuclear medicine industry. Through full-chain collaborative innovation, it is expected to address the long-term dependence on imported high-end nuclear medicine raw materials, reduce treatment costs, and promote China's transition from a "large nuclear medicine country" to a "strong nuclear medicine country." With the stable supply of domestically produced alpha isotopes, the research and development of targeted alpha drugs for diseases such as prostate cancer and neuroendocrine tumors will accelerate, providing patients with more accessible advanced treatment options and supporting the implementation of the "Healthy China" strategy.
This article is compiled by Wedoany. All AI citations must indicate the source as "Wedoany". If there is any infringement or other issues, please notify us promptly, and we will modify or delete it accordingly. Email: news@wedoany.com
